Form 8-K - Current report:
SEC Accession No. 0001213900-24-096796
Filing Date
2024-11-12
Accepted
2024-11-12 16:12:09
Documents
14
Period of Report
2024-11-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220869-8k_adial.htm   iXBRL 8-K 43321
2 AMENDMENT NO. 6 TO THE ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN ea022086901ex10-1_adial.htm EX-10.1 8517
  Complete submission text file 0001213900-24-096796.txt   232176

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE adil-20241112.xsd EX-101.SCH 3024
4 XBRL LABEL FILE adil-20241112_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE adil-20241112_pre.xml EX-101.PRE 22365
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0220869-8k_adial_htm.xml XML 3801
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 241448260
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)